Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 3/20 | 0.40 |
| ▸ | PLAU | P00749 | 3/20 | 0.40 |
| ▸ | KLKB1 | P03952 | 3/20 | 0.40 |
| ▸ | ELANE | P08246 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 4/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.32 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21826680 | 0.85 | F2 (0.43) | F2PLAUKLKB1ELANELMNA | |
| SCHEMBL21826682 | 0.85 | F2 (0.43) | F2PLAUKLKB1ELANELMNA | |
| SCHEMBL21826382 | 0.80 | F2 (0.48) | F2PLAUKLKB1ELANELMNA | |
| SCHEMBL21826394 | 0.80 | F2 (0.48) | F2PLAUKLKB1ELANELMNA | |
| SCHEMBL28771845 | 0.79 | LMNA (0.40) | F2PLAUKLKB1ELANELMNA | |
| SCHEMBL21825683 | 0.79 | F2 (0.44) | F2PLAUKLKB1ELANELMNA | |
| SCHEMBL21826733 | 0.79 | F2 (0.44) | F2PLAUKLKB1ELANELMNA | |
| SCHEMBL1862485 | 0.77 | LMNA (0.36) | ELANELMNAKMT2AALDH1A1MAPT | |
| SCHEMBL28618048 | 0.76 | F2 (0.43) | F2PLAUKLKB1ELANELMNA | |
| SCHEMBL20503558 | 0.74 | F2 (0.54) | F2PLAUKLKB1ELANELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7935699-B2 | Pyrazole glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2011-05-03 | — | — | US | disclosed |
| EP-2261216-A2 | Pyrazoles as glucokinase activators | F. Hoffmann-La Roche AG (CH) | 2010-12-15 | — | — | EP | disclosed |
| CN-101541756-A | Pyrazoles as glucokinase activators | HOFFMANN LA ROCHE (CH) | 2009-09-23 | — | — | CN | disclosed |
| US-20080021032-A1 | Pyrazole glucokinase activators | BERTHEL STEVEN JOSEPH | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021032-A1 | Pyrazole glucokinase activators | GCKR, GCK, GALK1 | F2 2844/4885PLAU 1115/4885KLKB1 894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.